San Francisco, CA, September 7, 2021 – FlemingMartin is pleased to announce that Nurix Therapeutics (NASDAQ: NRIX), a company focused on using small molecule drugs to activate or inhibit the natural process of protein degradation, has hired James Nelson as Vice President of Quality Assurance. In building and leading a proactive, best-in-class Quality Department at Nurix, James will help shape the Company as it develops and commercializes drugs to treat cancer.
James comes to Nurix possessing deep expertise across Quality Assurance, Quality Control, and Quality Systems, having worked his way up the corporate ladder at Neurocrine Biosciences, Arena Pharmaceuticals, and Seres Laboratories over the past 27 years. Moreover, James is known for developing robust and cohesive teams that have successfully balanced compliance with business needs. James has overseen the full scope of QA activities in support of multiple NDA submissions, he has collaborated with numerous regulatory agencies (FDA, MHRA, EMA, KFDA, Swiss Medic, ANVISA, etc.) worldwide, and he has audited manufacturing and clinical sites on five continents. A graduate of Sonoma State University, James earned dual degrees in Chemistry and Biology.
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Their small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for a broad range of diseases, including immune-oncology and autoimmune disease. To learn more, visit www.nurixtx.com.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. www.flemingmartin.com